Rafael Holdings (Rafael Holdings) Float Percentage Of Total Shares Outstanding : 77.16% (As of Jun. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rafael Holdings's float shares is 18.97 Mil. Rafael Holdings's total shares outstanding is 24.58 Mil. Rafael Holdings's float percentage of total shares outstanding is 77.16%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rafael Holdings's Insider Ownership is 8.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rafael Holdings's Institutional Ownership is 6.92%.

Rafael Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Rafael Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	18.97	/	24.58
	=	77.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rafael Holdings (Rafael Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 Broad Street, Newark, NJ, USA, 07102

Website

https://www.rafaelholdings.com

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Executives

I9 Plus, Llc	10 percent owner	153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas	director
Mary Margaret Huizinga	officer: Chief Devel. & Medical Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin	officer: Chief Legal Officer	C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik	officer: CHIEF EXECUTIVE OFFICER	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling	officer: Chief Commercial Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky	officer: Chief Financial Officer	90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash	director, officer: President	C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102